MedTrace Logo

Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire

NCT03614689 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 104

Last updated 2024-07-18

No results posted yet for this study

Summary

To analyze the proportion of hereditary tumors in ovarian cancer patients in China, as well as the spectrum of variations; the ctDNA characteristics in patients with ovarian cancer; the correlation between the clonal status of mutations and therapy response; whether ctDNA detection can be used to predict the risk of ovarian cancer recurrence; and the characteristics of immune repertoire before and after treatment in patients with ovarian cancer.

Conditions

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    collaborator OTHER

  • Geneplus-Beijing Co. Ltd.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-25
Primary Completion
2020-11-30
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03614689 on ClinicalTrials.gov